Cure My Disease

Don't miss your cure!

 Log in / Sign up

Healthy volunteers put an experimental drug under the microscope

NCT ID NCT07838987

Knowledge-focused Sponsor: Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

Researchers are running a Phase 1 trial to learn how the experimental oral drug TERN-701 behaves in healthy people. About 196 healthy adults receive single or repeated doses of TERN-701, sometimes with food, acid-reducing medicine, or other drugs. The team measures blood levels of the drug over time and tracks side effects to see how well people tolerate it.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TERN-701, an experimental oral drug also known as MK-4208
What this could lead to
If TERN-701 proves safe and predictable in the body, researchers could move it into trials with patients who have a disease it is designed to treat.
What could go wrong
This is an early Phase 1 study in healthy volunteers, so it cannot show whether the drug works for any condition. Many drugs at this stage cause unexpected side effects or fail in later testing.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

196 people

The number who actually took part.

Started

Dec 2023

Finished

Jun 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: The main inclusion criteria include but are not limited to the following: * Has body weight ≥48 kg (105.6 lbs) and body mass index within the range of 18.5 to 32 kg/m\^2 (inclusive) * Is in good health Exclusion Criteria: The main exclusion criteria include but are not limited to the following: * Has history or clinical manifestation of any metabolic, allergic, autoimmune, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, neurological, ocular, respiratory, endocrine, or psychiatric disorder, or any condition that would affect drug absorption, distribution, metabolism, or excretion (eg, stomach or intestinal surgery, or gallbladder removal/cholecystectomy). Uncomplicated appendectomy and hernia repair will be allowed. * Has history of QT prolongation syndrome, unexplained syncope, family history of sudden death, atrial fibrillation, malignant tumor, mental disorder, or any major disease * Has positive screening test for Hepatitis B surface antigen, anti-Hepatitis C virus antibodies, or anti-Human immunodeficiency virus (HIV) 1 and 2 antibodies * Has any known history of bleeding, or prothrombin time (TERN-701 + Probe Substrate Cocktail-2 arm only)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Healthy

Contacts and locations

Locations

  • ICON

    Millcreek, Utah, 84124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.